Oncotarget

Research Papers:

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro

Xiuli Feng, Yan Zhang, Tao Li and Yu Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:114292-114299. https://doi.org/10.18632/oncotarget.23224

Metrics: PDF 1281 views  |   HTML 1305 views  |   ?  


Abstract

Xiuli Feng1,2,*, Yan Zhang1,3,*, Tao Li1 and Yu Li1

1Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China

2Department of Respiratory Medicine, People’s Hospital of Qingzhou, Weifang, Shandong 262500, China

3The Fourth People’s Hospital of Jinan, Jinan, Shandong 250031, China

*These authors have contributed equally to this work

Correspondence to:

Yu Li, email: liyu796@163.com

Keywords: lung adenocarcinoma; sequence; chemotherapy

Received: April 20, 2017    Accepted: October 03, 2017    Published: December 14, 2017

ABSTRACT

Combination of chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had been proved to be a potent anti-drug for the treatment of tumors. However, survival time was not extended for the patients with lung adenocarcinoma (AdC) compared with first-line chemotherapy. In the present study, we attempt to assess the optimal schedule of the combined administration of pemetrexed and icotinib/erlotinib in AdC cell lines. Human lung AdC cell lines with wild-type (A549), EGFR T790M (H1975) and activating EGFR mutation (HCC827) were applied in vitro to assess the differential efficacy of various sequential regimens on cell viability, cell apoptosis and cell cycle distribution. The results suggested that the antiproliferative effect of the sequence of pemetrexed followed by icotinib/erlotinib was more effective than that of icotinib/erlotinib followed by pemetrexed. Additionally, a reduction of G1 phase and increased S phase in sequence of pemetrexed followed by icotinib/erlotinib was also observed, promoting cell apoptosis. Thus, the sequential administration of pemetrexed followed by icotinib/erlotinib exerted a synergistic effect on HCC827 and H1975 cell lines compared with the reverse sequence. The sequential treatment of pemetrexed followed by icotinib/erlotinib has been demonstrated promising results. This treatment strategy warrants further confirmation in patients with advanced lung AdC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23224